See What HealthDay Can Do For You
Contact Us

Hormone Agonists Helpful in Premenopausal Breast Cancer

Ovarian suppression may help treat patients if used in combination with standard therapies

FRIDAY, May 18 (HealthDay News) -- When used in combination with chemotherapy and tamoxifen, luteinizing-hormone-releasing hormone (LHRH) agonists are effective in treating hormone-receptor-positive breast cancer in premenopausal women, according to a meta-analysis published in the May 19 issue of The Lancet.

Jack Cuzick, Ph.D., of the University of London in the United Kingdom, and colleagues in the LHRH Agonists in Early Breast Cancer Overview group reviewed data from 16 trials comprising 11,906 premenopausal women with early breast cancer.

Used alone, the hormone agonists did not reduce recurrence or death after recurrence, but when used in combination with tamoxifen, chemotherapy or both, the agonists reduced recurrence by 12.7 percent and death after recurrence by 15.1 percent. The LHRH agonists had no effect on hormone-receptor-negative breast cancer.

"The results of our analysis show that LHRH agonists provide an effective additional class of agents for the treatment of premenopausal women with hormone-sensitive breast cancer," the authors conclude.

Chemotherapy followed by tamoxifen should remain the standard approach for women with higher-risk disease, but the addition of LHRH agonists for premenopausal women is worth considering, according to the authors of an accompanying editorial. "A century of research has taught us much about endocrine therapy for breast cancer, but the most important lessons about adjuvant ovarian suppression will be learnt over the next decade," they write.

Full Text (subscription or payment may be required)

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.